Patents by Inventor Kyung-A Kim

Kyung-A Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDE TARGETING FUSOBACTERIA, COMPOSITION FOR DIAGNOSING CANCER COMPRISING SAME, AND DRUG DELIVERY COMPOSITION
    Publication number: 20240402182
    Abstract: Provided are: a peptide targeting Fusobacteria, comprising a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 77 to 83; a composition for diagnosing cancer, comprising same; and a drug delivery composition. The peptide targeting Fusobacteria accurately targets Fusobacteria, which are harmful bacteria in various diseases, including cancer, and thus can be effectively used in cancer diagnosis and drug delivery.
    Type: Application
    Filed: October 11, 2022
    Publication date: December 5, 2024
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Han Sang KIM, Kyung-A KIM, Joong Bae AHN, Soon Myung PAIK, Dong Eun YONG, Hyukmin LEE
  • siRNA of NF-kB p105 for inhibiting cell proliferation and migration and a composition comprising same
    Patent number: 8242094
    Abstract: The present invention relates to a siRNA which targets mRNA of the NF-Kappa B p105 gene to cause its degradation by RNAi induction. In addition, the present invention provides a pharmaceutical composition for the treatment of diseases associated with aberrant cell proliferation and migration, comprising the siRNA and delivery vehicle capable of intracellular delivery of the same.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: August 14, 2012
    Assignee: Biopolymed, Inc.
    Inventors: Myung-Ok Park, Choun-Ki Joo, Jun-Sub Choi, Kyung-A Kim, Sung-Sik Bang
  • SIRNA OF NF-KB P105 FOR INHIBITING CELL PROLIFERATION AND MIGRATION AND A COMPOSITION COMPRISING SAME
    Publication number: 20110280929
    Abstract: The present invention relates to a siRNA which targets mRNA of the NF-Kappa B p105 gene to cause its degradation by RNAi induction. In addition, the present invention provides a pharmaceutical composition for the treatment of diseases associated with aberrant cell proliferation and migration, comprising the siRNA and delivery vehicle capable of intracellular delivery of the same.
    Type: Application
    Filed: August 22, 2008
    Publication date: November 17, 2011
    Inventors: Myung-Ok Park, Choun-Ki Joo, Jun-Sub Choi, Kyung-A Kim, Sung-Sik Bang